Trial Profile
A Single-center, Randomized, Blinded, Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in Single and Repeat Doses, With and Without Food, in Healthy Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 2849466 (Primary)
- Indications Cachexia; Heart failure
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 02 Mar 2015 Status changed from completed to discontinued.
- 10 Apr 2014 New trial record